The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Stand Up to Cancer and Boston College publish nursing training modules in immunotherapy

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

STAND UP TO CANCER published a series of Certification for Nursing Education training modules, with the Boston College William F. Connell School of Nursing, focused on immunotherapy.

The first web-based CNE modules will be available in July. In its first round, the program will seek to train 25 nurses working in immunotherapy. The program was announced as part of National Nurses Week, May 6-12.

The program will address providing care for cancer patients receiving immunotherapy, including education on immunology and related pathophysiology, symptom management, and nursing interventions to reduce symptom distress and promote wellness. The modules will meet CNE standards and each module will provide 3.5 to 5 contact hours from the Boston College William F. Connell School of Nursing.

Table of Contents

YOU MAY BE INTERESTED IN

Guest Editorial

Rathmell: We must support our junior colleagues
“Empathy and listening is a key place to start”

Just consider for a minute if this was the first year of running your lab, if you were on the job market as a physician or scientist right now, if you were a resident contemplating a career in cancer research after fellowship, if you were a graduate student or postdoc, if you were an undergraduate or a technician who was looking toward graduate school.
By W. Kimryn Rathmell
Guest Editorial

Weill Cancer Hub East to investigate connections between metabolism and anti-tumor immunity
Weill Cornell, Rockefeller, Princeton and the Ludwig Institute for Cancer Research showcase the power of collaboration

The immune system can be a powerful tool to control cancer. Immune cells within our body detect cancer cells and release payloads that kill them. Transformative science in the last decade has led to the development of therapies that enhance the ability of our immune cells to carry out this function. These therapies, including checkpoint blockade and CAR-T cells, have been lifesaving for many patients that before had untreatable cancer. But, sadly, a majority of patients with advanced solid tumors still succumb to their disease. 
By Jedd D. Wolchok, Joshua D. Rabinowitz and Sohail Tavazoie
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account